Systemic eligible psoriasis patients with comorbidities experience worse disease burden: Results from a large observational physician and patient survey - 11/08/17
Matthias Augustin, MD, University Medical Center Hamburg; Christopher Griffiths, MD, Dermatology Centre, Salford Royal Hospital, University of Manchester; Ricardo Romiti, MD, Department of Dermatology, Hospital das Clínicas University of São Paulo (USP); Esther Guevara-Sangines, MD, Hospital Regional “Lic. Adolfo López Mateos” ISSSTE; Seong-Jin Jo, MD, Department of Dermatology, Seoul National University Hospital; Tanya Howe, BS, GfK; Craig Richardson, Novartis Pharma AG; Haijun Tian, PhD, Novartis Pharmaceuticals Corporation; Luigi Naldi, MD, Department of Dermatology, Azienda Ospedaliera papa Giovanni XXIII
El texto completo de este artículo está disponible en PDF.| Commercial support: This study is syndicated in nature and the data are owned by GfK. This abstract was developed for and funded by Novartis Pharma AG, Basel, Switzerland. |
Vol 76 - N° 6S1
P. AB246 - juin 2017 Regresar al número
Artículo precedente
- Synergistic effect of combination deoxycholic acid and botulinum toxin for the treatment of submental fullness
- Systemic nickel allergy syndrome
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?